featured
Canagliflozin and Major Cardiovascular and Kidney Events in Patients With Different Baseline Levels of HbA1c, Disease Duration, and Treatment Intensity
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetologia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program
Diabetologia 2021 Nov 01;64(11)2402-2414, TK Young, JW Li, A Kang, HJL Heerspink, C Hockham, C Arnott, BL Neuen, S Zoungas, KW Mahaffey, V Perkovic, D de Zeeuw, G Fulcher, B Neal, M JardineFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.